drugset / Trial / NCT07241416
A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to compare the efficacy and safety of rezvilutamide with enzalutamide in the treatment of patients with low-volume metastatic hormone sensitive prostate cancer.
Timeline
- Start
- 2025-12-05
- Primary completion
- 2027-03
- Completion
- 2028-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Enzalutamide | Other / unclassified | — | Oral |
| Subject | Rezvilutamide | Small molecule | — | Oral |